Loading patent…
AssigneeAiCuris GmbH & Co. KG
InventorsYogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Susanne Bonsmann, Thomas Goldner
Estimating the term…
The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particulary infections caused by HSV-1 and HSV-2.
A sulfonate salt of the free base of N-[5-(amino-sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, wherein said sulfonate salt is benzenesulfonate salt having characteristic XRPD peaks at 7.7, 10.4, 10.7, 12.4, 15.5, 15.9, 17.8, 19.4, 19.8, 20.9, 23.1, 24.9, 25.3, 26.3 and 26.7 2theta as determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.
A sulfonate salt of the free base of N-[5-(amino-sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, wherein said sulfonate salt is mono ethane sulfonate having characteristic XRPD peaks at 6.6, 13.2, 19.8, 20.8, 21.2, 21.8, 22.7, 25.4, 25.8, 26.5, 29.4 and 33.3 2theta as determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.
A sulfonate salt of the free base of N-[5-(amino-sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, wherein said sulfonate salt is hemiethane-1,2-disulfonate having characteristic XRPD peaks at 10.6, 11.8, 12.4, 13.2, 16.3, 18.0, 19.1, 19.5, 20.1, 21.3, 21.8, 22.7, 23.7, 24.8 and 25.8 2theta as determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.
Dependencies are inferred from the claim text.